News | November 05, 2024
Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
It is the first autotaxin inhibitor to be investigated in cancer patients
Sharma joined the Morepen Lab in 2004
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Subscribe To Our Newsletter & Stay Updated
